Arca
Skip to content
Tools
Tools

Insomnia

Drug research and approvals for insomnia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 426 studies of insomnia are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 426
  • Trials authorized in Canada: 18
  • FDA orphan approvals: 0
  • EU medicines: 4

Recruiting now

Newest start dates first, of 426 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,128 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 253 whose ending is known, 66% met their primary endpoint, 5% missed it and 29% stopped early.

  • Completed, result not reported48543%
  • Ongoing27024%
  • Met its primary endpoint16715%
  • Status unknown12011%
  • Stopped: other or unclear424%
  • Stopped: enrollment or feasibility182%
  • Missed its primary endpoint121%
  • Stopped: sponsor or business decision91%
  • Stopped: funding40%
  • Stopped: lack of efficacy10%

Trials authorized in Canada

The 10 newest of 18; search them all in Canada trials
Jul 28, 2026An open-label, long-term extension study to investigate the safety, tolerability, and durability of treatment effect of alks 2680 in participants with…Alixorexton (alks 2680)AlkermesPending
Jul 18, 2025Double blind clinical trial of daridorexant for Alzheimer disease preventionDaridorexantDouglas Mental Health University InstituteOngoing
Jun 19, 2025Efficacy of trazodone in the treatment of insomnia in elderly people - a randomized controlled trial (tradition study)TrazodoneSanté Québec- Centre Hospitalier De L’université De MontréalOngoing
May 8, 2024Lemborexant for the treatment of residual insomnia in adequately treated major depressive disorder: a pilot randomized controlled trialLemborexantSt Michaels HospitalPending
Feb 23, 2024Cognitive behavioral therapy and trazodone effects on sleep and blood pressure in insomnia phenotypes based on objective sleep duration: a sequential…TrazodoneCentre De Recherche Cervo, Université LavalOngoing
Dec 20, 2023Lemborexant treatment of insomnia linked to epilepsyLemborexantUniversity of ManitobaOngoing
Jun 29, 2023The effects of lemborexant on the ability to sleep during daytime: a feasibility study to evaluate the potential of lemborexant to treat shift work disorderLemborexantCiusss Du Nord-De-L'Ile-De-Montréal - Hôpital Du Sacré-Coeur De Montréal.Closed
Aug 16, 2021A pilot, double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of a cannabis-infused oil for treatment of insomnia in major…Cannabis (CANNABIDIOL-DELTA-9-TETRAHYDROCANNABINOL)St. Joseph's Healthcare HamiltonOngoing
Jun 25, 2021Safety and efficacy of mirtazapine for treating chronic insomnia in the elderlyMirtazapineSanté Québec- Centre Hospitalier De L’université De MontréalPending
Oct 7, 2020A double-blind, randomized, parallel-group study with quetiapine extended release as comparator to evaluate the efficacy and safety of seltorexant 20 mg as…JNJ-42847922 (seltorexant)/ QuetiapineJohnson & JohnsonClosed

Medicines authorised in the EU

Newest first
Nov 7, 2022Melatonin NeurimMelatoninRAD Neurim Pharmaceuticals EEC SARLEMA ↗
Apr 29, 2022QuviviqDaridorexantIdorsia Pharmaceuticals Deutschland GmbHEMA ↗
Sep 20, 2018SlenytoMelatoninRAD Neurim Pharmaceuticals EEC SARLEMA ↗
Jun 29, 2007CircadinMelatoninRAD Neurim Pharmaceuticals EEC SARLEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.